Betrecep® (Tofacitinib) — First-in-Class JAK Inhibitor for Inflammatory Diseases

The World’s First Approved JAK Inhibitor — Oral Targeted Therapy Transforming Rheumatology and Gastroenterology

Betrecep® (Tofacitinib) is a potent, selective Janus kinase (JAK) inhibitor — the world’s first approved JAK inhibitor for any clinical indication — that predominantly inhibits JAK1 and JAK3, with functional selectivity over JAK2. By blocking JAK1 and JAK3 signalling, Tofacitinib interrupts the intracellular signalling cascade downstream of multiple pro-inflammatory cytokine receptors — simultaneously suppressing signalling from IL-2, IL-4, IL-6, IL-7, IL-9, IL-15, IL-21, IFN-γ, and other cytokines that drive the inflammatory processes underlying rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis.

Unlike conventional biologics (anti-TNF, anti-IL-6, anti-IL-17A antibodies) which target individual extracellular cytokines by injection or infusion, Tofacitinib is an orally administered small molecule that acts intracellularly — blocking the JAK-STAT signalling pathway used by multiple cytokine receptors simultaneously. This oral delivery and broad intracellular mechanism of action provides unique clinical advantages — once or twice daily tablet dosing, rapid onset of action, and modulation of multiple inflammatory pathways with a single medicine.

A.K. Pharma is a trusted medicine distributor in Delhi supplying genuine Betrecep (Tofacitinib) in both 5mg and 10mg tablet strengths to hospitals, rheumatology centres, gastroenterology units, and pharmacies across India. Manufactured by Pfizer India Ltd, Betrecep is the Indian brand of Tofacitinib — the same active ingredient as the internationally recognised Xeljanz — providing accessible pricing for Indian patients requiring JAK inhibitor therapy.

What is Betrecep (Tofacitinib)?

Betrecep contains Tofacitinib — a small molecule pyrrolopyrimidine compound that competitively and reversibly binds to the ATP-binding site of JAK1 and JAK3 kinase domains — inhibiting their catalytic activity and blocking downstream STAT phosphorylation and activation.

The JAK-STAT Pathway — Why It Matters in Inflammatory Disease:

The JAK-STAT (Janus Kinase — Signal Transducer and Activator of Transcription) pathway is a critical intracellular signalling cascade used by over 50 cytokines, growth factors, and hormones — including the majority of pro-inflammatory cytokines driving rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis.

Normal JAK-STAT Signalling:

1. Cytokine (e.g. IL-6, IL-2, IFN-γ) binds to its cell surface receptor
2. Receptor dimerisation → activation of receptor-associated JAK kinases (JAK1, JAK2, JAK3, or TYK2 — depending on receptor)
3. Activated JAKs trans-phosphorylate each other → full kinase activation
4. Activated JAKs phosphorylate STAT proteins (STAT1, STAT3, STAT4, STAT5, STAT6)
5. Phosphorylated STATs dimerize → translocate to nucleus → transcription of inflammatory genes (cytokines, chemokines, adhesion molecules, survival factors)

JAK-STAT in Autoimmune/Inflammatory Disease: In RA, PsA, AS, and UC — dysregulated cytokine production drives continuous pathological JAK-STAT activation:

• IL-6 → JAK1/JAK2 → STAT3 → acute phase response, synovial fibroblast activation, osteoclast activation
• IL-2, IL-15 → JAK1/JAK3 → STAT5 → T-cell and NK cell proliferation and survival
• IFN-γ → JAK1/JAK2 → STAT1 → macrophage activation, pro-inflammatory gene transcription
• IL-4, IL-13 → JAK1/JAK3 → STAT6 → Th2 responses, B-cell activation
• IL-12, IL-23 → JAK2/TYK2 → STAT4 → Th1/Th17 differentiation — relevant in psoriasis, AS, and UC

Tofacitinib’s Broad Cytokine Pathway Blockade: By inhibiting JAK1 and JAK3 — the two JAK kinases used by the common gamma chain (γc) receptor cytokines (IL-2, IL-4, IL-7, IL-9, IL-15, IL-21) and by IL-6 receptor (JAK1/JAK2) signalling — Tofacitinib simultaneously blocks multiple pro-inflammatory cytokine pathways with a single oral tablet. This broad pathway inhibition from one medicine is mechanistically distinct from biologics that each target only one cytokine or receptor.

Full prescribing information is available at the FDA label for Tofacitinib.

Clinical Studies and Evidence

ORAL Scan Trial (Tofacitinib in RA — Structural Protection) Published in Arthritis & Rheumatism (2012), the ORAL Scan trial demonstrated Tofacitinib 5mg and 10mg twice daily significantly inhibited radiographic progression (Sharp/van der Heijde score) in MTX-inadequate RA — establishing structural protection alongside symptomatic improvement.

ORAL Standard Trial (Tofacitinib vs Adalimumab in RA) Published in the New England Journal of Medicine (2012), the landmark ORAL Standard trial enrolled 717 MTX-inadequate RA patients — comparing Tofacitinib 5mg twice daily, Tofacitinib 10mg twice daily, Adalimumab 40mg Q2W, and placebo. Key results at month 6:

• ACR20 — 51.5% (Tofacitinib 5mg) and 52.6% (Tofacitinib 10mg) vs 47.2% (Adalimumab) vs 28.3% (placebo) — Tofacitinib non-inferior to Adalimumab
• DAS28 remission — 6.2% (5mg), 12.5% (10mg) vs 6.7% (Adalimumab) vs 1.1% (placebo)
• HAQ-DI improvement — significant vs placebo for both Tofacitinib doses
• Established Tofacitinib as comparable in efficacy to Adalimumab (the most prescribed anti-TNF) in MTX-inadequate RA — with the major advantage of oral administration

ORAL Solo Trial (Tofacitinib Monotherapy in RA) Published in Arthritis & Rheumatism (2012), the ORAL Solo trial demonstrated significant ACR20, ACR50, and ACR70 responses with Tofacitinib monotherapy vs placebo in MTX-inadequate or intolerant RA patients — establishing Tofacitinib as effective as monotherapy when MTX is not tolerated.

OPAL Broaden Trial (Tofacitinib in Psoriatic Arthritis After csDMARD Failure) Published in the Lancet (2017), the OPAL Broaden trial enrolled 422 patients with active PsA who had failed csDMARD therapy — comparing Tofacitinib 5mg, 10mg twice daily, Adalimumab, and placebo. Key results at month 3:

• ACR20 — 50% (5mg), 61% (10mg) vs 52% (Adalimumab) vs 33% (placebo) — significantly superior to placebo; comparable to Adalimumab
• PASI75 — significant improvement in psoriatic skin disease
• MDA (Minimal Disease Activity) — significantly more patients achieving MDA vs placebo
• Established Tofacitinib as effective in PsA — both joint and skin manifestations

OPAL Beyond Trial (Tofacitinib in PsA After Anti-TNF Failure) Published in Annals of the Rheumatic Diseases (2017), OPAL Beyond demonstrated Tofacitinib significantly improved ACR20 vs placebo in anti-TNF-experienced PsA patients — establishing Tofacitinib as an effective oral option after anti-TNF failure in PsA.

OCTAVE Induction and Sustain Trials (Tofacitinib in Ulcerative Colitis) Published in the New England Journal of Medicine (2017), the OCTAVE trials were pivotal Phase 3 trials in 1,139 patients with moderately-to-severely active UC who had failed or were intolerant to conventional therapy. Key results:

• Remission at week 8 (induction) — 18.5% (10mg) vs 8.2% (placebo); 16.6% (10mg) vs 3.6% (placebo) — significantly superior in both induction trials
• Remission at week 52 (maintenance) — 34.3% (5mg), 40.6% (10mg) vs 11.1% (placebo) — significantly superior
• Mucosal healing — significantly improved vs placebo at both induction and maintenance
• Established Tofacitinib as the first oral JAK inhibitor approved for UC — a highly significant advance in inflammatory bowel disease management for patients failing biologics

Ankylosing Spondylitis — Phase 2/3 Data: Clinical trial data demonstrated Tofacitinib significantly improved ASAS20 and ASAS40 in patients with active AS — leading to approval for this indication in multiple countries including India.

Available Strengths

Betrecep is available in the following tablet strengths:

Both strengths are available from A.K. Pharma — providing complete dosing flexibility across all approved indications.

Indications — What Betrecep is Used For

Rheumatoid Arthritis:

• Moderate-severe active RA in adults — in combination with Methotrexate or as monotherapy in patients intolerant to MTX
• After inadequate response to one or more conventional DMARDs
• Dose: 5mg twice daily

Psoriatic Arthritis:

• Active PsA in adults — in combination with conventional synthetic DMARDs (Methotrexate)
• After inadequate response to csDMARD therapy
• Dose: 5mg twice daily

Ankylosing Spondylitis:

• Active AS in adults — after inadequate response to NSAID therapy
• Dose: 5mg twice daily

Ulcerative Colitis:

• Moderately to severely active UC in adults — after failure of conventional therapy or biologics
• Induction dose: 10mg twice daily for 8 weeks (or 16 weeks if needed)
• Maintenance dose: 5mg twice daily (10mg twice daily for patients who have lost response to 5mg)

Polyarticular-Course Juvenile Idiopathic Arthritis (pcJIA):

• Active pcJIA in patients ≥2 years — in combination with MTX
• Weight-based dosing for paediatric patients

For detailed indication information refer to MedlinePlus Tofacitinib.

Key Benefits of Betrecep

First-in-Class JAK Inhibitor — Pioneering Oral Targeted Therapy Tofacitinib was the world’s first JAK inhibitor approved for any indication — pioneering an entirely new class of targeted immunosuppressants. Before JAK inhibitors, oral targeted therapy for RA, PsA, and UC did not exist — patients requiring targeted therapy needed injections or infusions. Tofacitinib’s oral availability fundamentally changed the treatment landscape.

Broad Multi-Cytokine Pathway Inhibition From One Oral Tablet By inhibiting JAK1 and JAK3 — shared by receptors for IL-2, IL-4, IL-6, IL-7, IL-9, IL-15, IL-21, and IFN-γ — Tofacitinib simultaneously suppresses multiple key inflammatory pathways driving RA, PsA, AS, and UC. This breadth of pathway inhibition from a single oral tablet is mechanistically superior to single-cytokine biologic targeting for diseases driven by multiple overlapping inflammatory mediators.

Comparable Efficacy to Adalimumab With Oral Convenience The ORAL Standard trial demonstrates Tofacitinib 5mg twice daily is non-inferior to Adalimumab (the most prescribed anti-TNF biologic) for ACR20 in MTX-inadequate RA — with the major practical advantage of oral tablet administration vs subcutaneous injection every 2 weeks.

First Oral Therapy Approved for Ulcerative Colitis Tofacitinib was the first oral targeted therapy approved for UC — providing a critically important oral option for patients with moderate-severe UC who have failed conventional therapy (aminosalicylates, corticosteroids, azathioprine) and biologics (anti-TNF, anti-integrin). Before Tofacitinib, all approved targeted therapies for UC required injection or infusion.

Rapid Onset of Action JAK inhibitors achieve rapid therapeutic response — significant improvements in joint symptoms and inflammatory markers typically seen within 2-4 weeks. This rapid onset is faster than many conventional DMARDs and comparable to biologic therapies.

Effective in Both Biologic-Naive and Biologic-Experienced Patients Tofacitinib demonstrates efficacy in both biologic-naive patients and those who have failed prior anti-TNF or other biologic therapy — providing an important oral option at multiple stages of the treatment algorithm for RA, PsA, and UC.

Oral Administration — No Injection Required Twice-daily oral tablet administration eliminates the need for subcutaneous injections or intravenous infusions — significantly improving patient comfort, convenience, and independence from clinical visits for drug administration.

Both 5mg and 10mg Available From A.K. Pharma A.K. Pharma supplies both Betrecep 5mg and 10mg — enabling complete dose management across all indications including UC induction (10mg) and maintenance (5mg), and dose escalation options in RA.

How Betrecep Works — JAK-STAT Pathway Inhibition

Step 1 — JAK Kinase ATP Site Binding: Tofacitinib enters cells and binds competitively to the ATP-binding cleft of JAK1 and JAK3 kinase domains — preventing ATP from binding. Without ATP, JAK1 and JAK3 cannot perform phosphoryl transfer — the kinases are catalytically inactive.

Step 2 — Trans-phosphorylation Blockade: Normally, cytokine receptor binding leads to JAK-JAK trans-phosphorylation (activation loop phosphorylation) — amplifying JAK kinase activity. Tofacitinib prevents this trans-phosphorylation — JAK kinases remain in their low-activity baseline state even after cytokine receptor occupancy.

Step 3 — STAT Phosphorylation Blockade: Without active JAK kinases, STAT proteins (STAT1, STAT3, STAT4, STAT5, STAT6) — the substrates of JAK kinases — cannot be phosphorylated on their activating tyrosine residues. Unphosphorylated STATs cannot dimerize or translocate to the nucleus.

Step 4 — Inflammatory Gene Transcription Suppression: Without nuclear STAT dimers, STAT-responsive inflammatory genes are not transcribed — production of inflammatory cytokines (IL-6, TNF, IL-17), chemokines (CXCL8, CCL2), acute phase proteins (CRP, fibrinogen), and survival factors (BCL-2, MCL-1) is reduced.

Step 5 — Downstream Inflammatory Suppression: Reduced inflammatory gene transcription leads to:

• RA/PsA/AS: Reduced synovial fibroblast activation, reduced osteoclast activation, reduced bone erosion, reduced enthesitis
• UC: Reduced intestinal epithelial inflammation, reduced mucosal immune cell infiltration, reduced intestinal permeability disruption, mucosal healing

JAK Selectivity Profile: Tofacitinib preferentially inhibits JAK1 and JAK3 > JAK2 and TYK2. The relative sparing of JAK2 (which mediates erythropoietin and thrombopoietin signalling) helps preserve erythropoiesis and thrombopoiesis — though haematological monitoring is still required. The relative sparing of TYK2 (which mediates IFN-α/β antiviral signalling) means Tofacitinib has less impact on antiviral innate immunity than TYK2-inhibiting agents.

For detailed mechanism overview refer to EULAR RA Management Recommendations and ACR RA Treatment Guidelines.

Betrecep vs Biologic DMARDs — Key Practical Comparison

Dosage and Administration

Rheumatoid Arthritis:

• 5mg orally twice daily — with or without food
• With Methotrexate or as monotherapy
• Reduce to 5mg once daily in patients taking moderate CYP3A4 inhibitors + CYP2C19 inhibitors, or strong CYP3A4 inhibitors

Psoriatic Arthritis:

• 5mg orally twice daily — with conventional synthetic DMARD (typically Methotrexate)

Ankylosing Spondylitis:

• 5mg orally twice daily

Ulcerative Colitis:

• Induction: 10mg orally twice daily for 8 weeks — may extend to 16 weeks if insufficient response at 8 weeks
• Maintenance: 5mg orally twice daily — use lowest effective dose; use 10mg twice daily for patients who have lost response to 5mg and for whom benefits outweigh risks

Paediatric pcJIA (≥2 years):

• Weight-based dosing — 3.2mg twice daily (<20kg), 4mg twice daily (20-<40kg), 5mg twice daily (≥40kg)

Administration:

• Take at approximately the same time each day — morning and evening approximately 12 hours apart
• With or without food — food does not significantly affect Tofacitinib absorption
• Swallow tablets whole — do not crush or chew

Dose Reductions Required In:

• Moderate hepatic impairment — reduce to 5mg once daily
• Severe renal impairment or haemodialysis — reduce to 5mg once daily
• Co-administration with strong CYP3A4 inhibitors — reduce to 5mg once daily
• Co-administration with moderate CYP3A4 + potent CYP2C19 inhibitors — reduce to 5mg once daily

Monitoring Schedule:

Full dosing guidelines available at Drugs.com Tofacitinib Dosage.

Critical Safety — Black Box Warnings

Tofacitinib carries four Black Box Warnings — the most important safety information for prescribers:

1. Serious Infections: Patients treated with Tofacitinib are at increased risk of serious infections — including bacterial, mycobacterial (TB), fungal, and viral infections — that may lead to hospitalisation or death. Do not initiate Tofacitinib in patients with active serious infection. Interrupt Tofacitinib if a serious infection develops. Mandatory TB screening before starting.

2. Mortality: In a post-marketing safety study (ORAL Surveillance) in RA patients ≥50 years with at least one cardiovascular risk factor, Tofacitinib 10mg twice daily was associated with higher all-cause mortality compared to anti-TNF therapy. Use the lowest effective dose and limit use of 10mg twice daily to UC induction only.

3. Major Adverse Cardiovascular Events (MACE): In the ORAL Surveillance study, Tofacitinib was associated with increased risk of MACE (heart attack, stroke, cardiovascular death) compared to anti-TNF therapy — particularly in patients ≥65 years, current or past smokers, and those with cardiovascular risk factors. Careful benefit-risk assessment is required in these patients.

4. Malignancy Including Lymphoma and Lung Cancer: Tofacitinib is associated with increased risk of malignancies — including lymphoma and lung cancer. Risk is higher at 10mg twice daily than 5mg twice daily. Avoid use in patients with known malignancy (other than successfully treated non-melanoma skin cancer).

5. Thrombosis (DVT and PE): Tofacitinib — particularly at 10mg twice daily — is associated with increased risk of deep vein thrombosis (DVT) and pulmonary embolism (PE). Avoid use in patients at high risk of thrombosis. Do not use 10mg twice daily outside UC induction indication in patients with thrombosis risk factors.

Pre-Treatment Screening — Essential Before Starting Betrecep

All patients must be screened before initiating Betrecep:

• Tuberculosis — Mandatory TST or IGRA + chest X-ray. Treat latent TB before starting. Active TB — do not initiate
• Hepatitis B and C — Screen HBsAg, anti-HBc, anti-HBs, anti-HCV before starting
• CBC — Baseline neutrophil count, lymphocyte count, haemoglobin — do not initiate if ANC <1000/mm³, ALC <500/mm³, or Hgb <8g/dL
• LFTs — Baseline liver function
• Lipids — Baseline fasting lipid profile — Tofacitinib increases LDL, HDL, and total cholesterol
• Cardiovascular risk assessment — Particularly important given MACE Black Box Warning

Who Should Use Betrecep

Betrecep is prescribed for:

RA — Preferred Clinical Scenarios:

• Adults with moderate-severe RA after inadequate response to Methotrexate or other csDMARDs — oral alternative to biologic DMARDs
• Patients who prefer or require oral therapy over injectable biologics
• Patients who have failed one or more anti-TNF biologics — different mechanism provides no cross-resistance
• Patients where MTX is not tolerated — Tofacitinib monotherapy is approved

PsA:

• Adults with active PsA after csDMARD failure — oral option alongside or after anti-TNF and anti-IL-17A biologics
• Patients with predominantly joint (vs skin) manifestations — where IL-17A inhibitors’ skin benefit is less relevant

AS:

• Adults with active AS after NSAID failure — oral alternative to anti-TNF and anti-IL-17A biologics

UC:

• Adults with moderately-severely active UC after failing conventional therapy and/or biologics
• First oral targeted therapy for UC — particularly valuable for patients who prefer oral therapy or where biologics have failed

Patients Requiring Special Consideration:

• Patients ≥65 years or with CV risk factors — careful benefit-risk assessment against MACE risk; consider anti-TNF biologic as alternative
• Patients with active or recent malignancy — generally avoid
• High DVT/PE risk patients — generally avoid 10mg dose; carefully assess 5mg risk

Betrecep is prescribed by rheumatologists, gastroenterologists, and dermatologists. A.K. Pharma supplies Betrecep to hospitals, rheumatology centres, gastroenterology units, and pharmacies across Delhi and India.

Possible Side Effects

Common side effects include upper respiratory tract infection (17-18%), diarrhoea (4%), headache (4%), nasopharyngitis (3-4%), and hypertension (2%).

Serious side effects — see Black Box Warnings above — including:

• Serious infections — bacterial, mycobacterial, opportunistic — most clinically important safety concern in daily practice
• MACE — increased cardiovascular event risk — monitor cardiovascular risk factors
• Malignancy — lymphoma and lung cancer — avoid in patients with prior malignancy
• Thrombosis — DVT and PE — monitor for symptoms; avoid high-dose in high-risk patients
• Gastrointestinal perforation — reported in patients with concomitant NSAID use; use with caution in patients at risk
• Hepatotoxicity — ALT/AST elevation — LFT monitoring required
• Haematological effects — lymphopenia, neutropenia, anaemia — CBC monitoring required
• Lipid elevations — LDL, total cholesterol increases — lipid monitoring and management required

Full side effect information available at FDA Tofacitinib Safety Information.

Precautions

• Mandatory TB screening — before starting; treat latent TB first; active TB — do not start
• Hepatitis B/C — screen before starting; monitor carriers during treatment
• CBC monitoring — do not start if ANC <1000/mm³ or ALC <500/mm³; interrupt for significant drops during treatment
• Lipid monitoring — baseline and 4-8 weeks after starting; manage hyperlipidaemia as clinically indicated
• Cardiovascular risk — careful assessment in patients ≥65 years, smokers, prior CV history — consider anti-TNF as alternative
• DVT/PE risk — avoid 10mg twice daily outside UC induction in patients with thrombosis risk factors; discontinue if thrombosis occurs
• Live vaccines — avoid during treatment; complete before starting
• Strong CYP3A4 inhibitors — reduce dose to 5mg once daily
• Pregnancy — avoid; effective contraception required during and for at least 4 weeks after last dose — animal data shows embryo-foetal harm
• Breastfeeding — discontinue during treatment and for at least 18 hours (5mg) or 36 hours (10mg) after last dose
• Refer to EULAR RA Management Recommendations for complete management context

Storage and Handling

• Store at room temperature below 30°C
• Keep in original packaging — protect from moisture and light
• Keep out of reach of children
• No cold chain required — room temperature oral tablet formulation

As a responsible medicine distributor in Delhi, A.K. Pharma stores all medicines including Betrecep under manufacturer-recommended conditions ensuring product integrity for every supply.

Manufacturer Information

Betrecep (Tofacitinib) is manufactured by Pfizer India Ltd — the Indian subsidiary of Pfizer Inc., the global pharmaceutical company that discovered and developed Tofacitinib. Tofacitinib received FDA approval in November 2012 for moderate-severe RA — the world’s first approved JAK inhibitor — with subsequent approvals for PsA (2017), UC (2018), AS (2020), and pcJIA (2020). A.K. Pharma supplies only genuine Betrecep sourced from authorized Pfizer distributors.

Related Immunosuppressant and Arthritis Medicines Available at A.K. Pharma

• Simponi (Golimumab) — anti-TNF biologic for RA, PsA, AS — once-monthly SC
• Scapho (Secukinumab) — anti-IL-17A for PsA, AS, and psoriasis
• Copellor (Ixekizumab) — anti-IL-17A for PsA, AS, and psoriasis
• Dupixent (Dupilumab) — anti-IL-4/IL-13 for atopic dermatitis
• Browse all Immunosuppressant Medicines available at A.K. Pharma

Frequently Asked Questions

Q. What is Betrecep used for? Betrecep (Tofacitinib) is used to treat moderate-severe rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis, moderately-to-severely active ulcerative colitis, and polyarticular-course juvenile idiopathic arthritis. More information available at MedlinePlus.

Q. What is the generic name of Betrecep? The generic name of Betrecep is Tofacitinib. It is a JAK1/JAK3 inhibitor — the world’s first approved JAK inhibitor — manufactured by Pfizer India Ltd. The same active ingredient is sold internationally as Xeljanz.

Q. How does Betrecep work? Betrecep blocks JAK1 and JAK3 — two kinases that transmit signals from multiple pro-inflammatory cytokine receptors inside cells. By blocking these kinases, Betrecep simultaneously suppresses signalling from IL-2, IL-4, IL-6, IL-7, IL-9, IL-15, IL-21, IFN-γ, and other cytokines driving inflammation — reducing inflammatory gene transcription and suppressing the autoimmune processes underlying RA, PsA, AS, and UC.

Q. How is Betrecep different from anti-TNF biologics like Simponi? Betrecep is an oral tablet taken twice daily — no injections required. It acts intracellularly blocking multiple cytokine pathways simultaneously (JAK1/JAK3), whereas anti-TNF biologics like Simponi (Golimumab) are injected subcutaneously and target only TNF-α. Both are effective in RA and PsA but differ in mechanism, route of administration, and safety profile. Betrecep carries additional Black Box Warnings for MACE, malignancy, and thrombosis that require careful patient selection.

Q. What are the Black Box Warnings for Betrecep? Betrecep carries Black Box Warnings for: serious infections (including TB), increased mortality (particularly at 10mg dose in patients ≥50 with CV risk factors), major adverse cardiovascular events (MACE — heart attack, stroke), malignancy (lymphoma, lung cancer), and thrombosis (DVT and PE). Careful patient selection and pre-treatment screening are essential.

Q. What is the difference between the 5mg and 10mg doses? 5mg twice daily is the standard dose for RA, PsA, and AS — and the maintenance dose for UC. 10mg twice daily is used only for UC induction (8-16 weeks) — it carries higher risks of MACE, malignancy, and thrombosis and should not be used at 10mg twice daily outside the UC induction indication. The 10mg dose should not be used in patients with known CV risk factors, malignancy history, or high thrombosis risk.

Q. Is TB screening required before starting Betrecep? Yes — mandatory TB screening with TST or IGRA plus chest X-ray is required before starting Betrecep. Latent TB must be treated before initiating Tofacitinib. Active TB is a contraindication. This is particularly important in India where TB prevalence is high.

Q. Is Betrecep available in India? Betrecep can be supplied to hospitals, rheumatology centres, gastroenterology units, and pharmacies across India through licensed pharmaceutical distributors. Contact A.K. Pharma — medicine distributor in Delhi — for availability and pricing.

Q. What is the price of Betrecep in India? Betrecep price in India varies by strength (5mg or 10mg) and pack size. Contact A.K. Pharma at 011 4172 6999 or WhatsApp +91 9810034827 for current pricing and bulk supply rates.

Q. How to order Betrecep from A.K. Pharma? You can request a quote directly from this page, call us at 011 4172 6999, or WhatsApp us at +91 9810034827 with your requirements and we will respond promptly.

Q. Does A.K. Pharma supply Betrecep in bulk? Yes. A.K. Pharma supplies Betrecep in bulk to rheumatology centres, gastroenterology units, hospitals, and pharmacies across Delhi and India. Contact us for bulk pricing and availability.

Why Order Betrecep from A.K. Pharma?

• Licensed medicine distributor in Delhi with all required drug licenses
• 100% genuine Betrecep sourced from authorized Pfizer India distributors
• Both 5mg and 10mg tablet strengths available — complete dosing flexibility
• Room temperature storage — no cold chain required
• Available alongside the complete rheumatology portfolio — Simponi, Scapho, Copellor
• Bulk supply available for hospitals and rheumatology/gastroenterology centres
• Prompt response to all quote requests
• Serving rheumatologists and gastroenterologists across Delhi NCR and India

Contact A.K. Pharma for Betrecep Supply 📍 E-2/257A, 2nd Floor, Shastri Nagar, New Delhi 110052 📞 011 4172 6999 📱 WhatsApp: +91 9810034827 🌐 akpharma.in